Neurogene (NGNE) Fundamental Analysis: Revenue, Earnings & Valuation

5.74 / 10

Netural

Fundamental analysis rates NGNE as neutral with a 5.7/10 quality score. Strengths include PB‑ROE, cash‑to‑market, inventory and fixed‑asset turnover, and strong YoY revenue growth. Weak points are high income‑tax ratio, low gross margin and revenue‑to‑market, suggesting guarded outlook.

Analysis Checks(7/10)

Revenue-MV

Value-0.11

Score1/3

Weight11.63%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight3.00%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight15.42%

1M Return6.74%

Gross profit margin (%)

Value41.83

Score1/3

Weight-1.09%

1M Return-0.63%

PB-ROE

Value0.00

Score2/3

Weight14.59%

1M Return6.97%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-0.89%

1M Return-0.50%

Fixed assets turnover ratio

Value9306.28

Score3/3

Weight1.99%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight8.92%

1M Return4.32%

Asset-MV

Value-0.55

Score3/3

Weight32.73%

1M Return11.84%

Cash-MV

Value0.02

Score2/3

Weight13.70%

1M Return5.94%

Is NGNE undervalued or overvalued?

NGNE scores 5.74/10 on fundamentals and holds a Fair valuation at present. Backed by its -31.41% ROE, 0.00% net margin, -3.73 P/E ratio, 1.27 P/B ratio, and 0.93% earnings growth, these metrics solidify its Netural investment rating.